Patent SG-11201903407X-A (SG)
Title: Secretable variant immunomodulatory proteins and engineered cell therapy
Inventor: SWANSON RYAN
IPC: C07K14/47
Filed: 2017-10-20
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 Organization 0 11101 HOE 3E1 0 011101 Ell IM MO HER 11110 1111 OEN International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/075978 Al 26 April 2018 (26.04.2018) WIP0 I PCT (51) International Patent Classification: (74) Agent: POTTER, Karen et al.; Morrison & Foerster C12N 15/12 (2006.01) CO7K 14/705 (2006.01) LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA C12N 15/86 (2006.01) A61K 38/17 (2006.01) 92130-2040 (US). C07K 14/47 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2017/057743 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 20 October 2017 (20.10.2017) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (25) Filing Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (30) Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/410,827 20 October 2016 (20.10.2016) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/475,210 22 March 2017 (22.03.2017) US (84) Designated States (unless otherwise indicated, for every 62/537,921 27 July 2017 (27.07.2017) US kind of regional protection available): ARIPO (BW, GH, (71) Applicant: ALPINE IMMUNE SCIENCES, INC. GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, [US/US]; 201 Elliott Avenue West, Suite 230, Seattle, WA UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 98119 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (72) Inventors: SWANSON, Ryan; c/o Alpine Immune MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Sciences, Inc., 201 Elliott Avenue West, Suite 230, Seattle, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = WA 98119 (US). KORNACKER, Michael; c/o Alpine Im-KM, ML, MR, NE, SN, TD, TG). = mune Sciences, Inc., 201 Elliott Avenue West, Suite 230, Seattle, WA 98119 (US). _ = Title: SECRETABLE VARIANT IMMUNOMODULATORY PROTEINS AND ENGINEERED CELL THERAPY (54) (57) : Provided are immunomodulatory proteins, nucleic FIG. 4A acids encoding such immunomodulatory proteins, cells engineered _ to express the immunomodulatory proteins and infections agents = containing nucleic acid encoding the immunomodulatory proteins. In some embodiments, the immunomodulatory proteins are secretable. In some embodiments, the immunomodulatory proteins are trans- = — = membrane proteins that are surface expressed. The immunomodula- = Secimd T c ' tory proteins, engineered cells and infectious agents provide thera- _ peutic utility for a variety of immunological and oncological condi- = Activating tions. Compositions and methods for making and using such proteins = receptor are provided. = CR or C secreted = = Activating/ vIgD (SIP) 1-1 Receptor , tz. First T eel l I , I IN © -.... ,-1 © ei O [Continued on next page] WO 2018/075978 Al MIDEDIMOMOIDEIREIDIONONIMOMEMOVOIS Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of earlier application (Rule 4.17(iii)) he Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))